Abstract
Esophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with limited effective therapeutic options for patients with locally advanced unresectable disease. The study by Wei et al, featured in this issue, highlights the potential of induction chemoimmunotherapy followed by definitive radiotherapy or concurrent chemoradiotherapy to improve treatment outcomes in this challenging patient population. This retrospective analysis of 132 patients demonstrates promising results, including a median progression-free survival of 14.2 months and overall survival of 19.9 months, alongside an acceptable safety profile. Notably, the study identifies the effectiveness of induction therapy and maintenance immunotherapy as key prognostic factors, emphasizing the synergistic potential of integrating immune checkpoint inhibitors with radiotherapy. While these findings are encouraging, they require further validation through prospective trials, along with biomarker-based and immune response studies, to refine patient selection and maximize therapeutic benefits. This editorial explores the implications of this research, its impact on clinical practice, and future directions for advancing the treatment landscape of ESCC.